Emerging MRI-Based Technology for Assessing Muscle and Fat Gets FDA 510(k) Clearance
Utilizing biomarkers from magnetic resonance imaging (MRI) exams, AMRA Medical’s BCP Scan reportedly provides precise measurements of muscle and fat.
The Food and Drug Administration (FDA) has granted 510(k) clearance to the BCP (Body Composition Profile) Scan, a technology that enables clinicians to obtain accurate muscle and fat measurements from magnetic resonance imaging (MRI), according to AMRA Medical.
In contrast to obtaining a body mass index (BMI) or waist circumference number, AMRA Medical said its BCP Scan offers specific measurements of muscle, fat, and liver fat volumes. The company noted these measurements may help clinicians educate patients on associated health risks and initiate conversations about lifestyle changes to mitigate these risks.
For example, the BCP Scan can reportedly identify people with high visceral fat and low liver fat, a combination associated with a high heart disease risk, according to AMRA Medical. The company also suggested that the BCP Scan can help monitor weight loss efforts for obese people by determining whether they are losing visceral fat or if they are only losing subcutaneous fat.
AMRA Medical says its protocol for the BCP Scan only adds a couple of minutes to a prescribed MRI exam and generates a report that compares the patient’s body composition measurements to normative values from the company’s reference database as well as others of the same sex and body habitus.
FDA Clears Enhanced MRI-Guided Laser Ablation System
June 5th 2025An alternative to an open neurosurgical approach, the Visualase V2 MRI-Guided Laser Ablation System reportedly utilizes laser interstitial thermal therapy (LITT) for targeted soft tissue ablation in patients with brain tumors and focal epilepsy.
Can Abbreviated MRI Have an Impact in Differentiating Intraductal Papilloma and Ductal Secretion?
June 3rd 2025For patients with inconclusive ultrasound results, abbreviated breast MRI offers comparable detection of intraductal papilloma as a full breast MRI protocol at significantly reduced times for scan acquisition and interpretation, according to a new study.
FDA Issues Expanded Pediatric Approval of MRI Contrast Agent for Lung Ventilation Assessment
June 2nd 2025Previously approved for MRI lung ventilation evaluation in adults and children 12 and older, the hyperpolarized contrast agent Xenoview can now be utilized for pediatric patients six years and older.
